Flo Health partners with company to develop digital tool that screens for heavy menstrual bleeding

Flo Health, creator of the popular Flo app, and biopharmaceutical company Myovant Sciences are partnering together to create a digital tool that screens women for heavy menstrual bleeding.

The companies announced their deal on Monday, Oct. 8, with the goal of addressing the condition that affects about 25 percent of women and is associated with uterine fibroids. The digital tool will be embedded into the Flo app and help women keep track of their menstrual bleeding, identify any concerns and connect them to a healthcare professional.

"We are pleased to enter into this first-of-its-kind partnership, combining Myovant's clinical development expertise with Flo's innovative technology,” Lynn Seely, MD, Myovant Sciences president and chief executive officer, said in a statement. “Our aim is for this initiative to result in important insights and data that will empower women to take a more proactive role in their personal health.”

The Flo app is a platform that uses data science and artificial intelligence (AI) to help women track their ovulation and period cycle. By using AI, the app provides personalized content to specific users. According to its website, it has 22 million monthly users and 5 million daily users.

Myovant Sciences is a clinical-stage biotechnology company that focuses on developing and commercializing innovative therapies for women’s health and endocrine diseases.

"We share Myovant's mission of empowering women to take charge of their health, including in the area of tracking and better understanding heavy menstrual bleeding," Flo Health President Yuri Gurski said in a statement. "By partnering with Myovant to create improved digital tools for evaluating and researching periods, we are moving closer to achieving this mission."  

""

Danielle covers Clinical Innovation & Technology as a senior news writer for TriMed Media. Previously, she worked as a news reporter in northeast Missouri and earned a journalism degree from the University of Illinois at Urbana-Champaign. She's also a huge fan of the Chicago Cubs, Bears and Bulls. 

Around the web

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”